Home
Register
Log inPfizer Course Has 23% Efficacy Vs. Omicron in S. African Study
Page 1 of 1 • Share
Pfizer Course Has 23% Efficacy Vs. Omicron in S. African Study
by 8DonCo Sun Dec 12, 2021 4:49 pm
(Bloomberg) -- A two-shot course of Pfizer Inc.’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa.
Researchers at the Africa Health Research Institute in Durban issued additional data on a small study released earlier this week.
The research considered blood plasma samples from 12 participants. Scientists found omicron resulted in about a 41-fold reduction in levels of neutralizing antibodies produced by people who had received two doses of the Pfizer-BioNTech SE shot, compared with the strain detected in China almost two years ago.
This is “essentially compromising the ability of the vaccine to protect against infection,” said the team of scientists led by laboratory head Alex Sigal in a preprint released on Friday.
There continues to be sufficient protection against severe disease, they said.
The team this week was the first to show that the variant, found by scientists in South Africa and Botswana and announced on Nov. 25, could largely, but not totally, escape the antibodies produced by Pfizer’s vaccine. Still, they said a booster shot could increase immunity. That’s been backed up by studies carried out by Pfizer itself.
Preliminary U.K. data released on Friday showed that boosters from AstraZeneca Plc and Pfizer/BioNTech SE improve protection against the omicron variant to as much as 75% in the early days after the shot.
Researchers at the Africa Health Research Institute in Durban issued additional data on a small study released earlier this week.
The research considered blood plasma samples from 12 participants. Scientists found omicron resulted in about a 41-fold reduction in levels of neutralizing antibodies produced by people who had received two doses of the Pfizer-BioNTech SE shot, compared with the strain detected in China almost two years ago.
This is “essentially compromising the ability of the vaccine to protect against infection,” said the team of scientists led by laboratory head Alex Sigal in a preprint released on Friday.
There continues to be sufficient protection against severe disease, they said.
The team this week was the first to show that the variant, found by scientists in South Africa and Botswana and announced on Nov. 25, could largely, but not totally, escape the antibodies produced by Pfizer’s vaccine. Still, they said a booster shot could increase immunity. That’s been backed up by studies carried out by Pfizer itself.
Preliminary U.K. data released on Friday showed that boosters from AstraZeneca Plc and Pfizer/BioNTech SE improve protection against the omicron variant to as much as 75% in the early days after the shot.
_________________
8DonCo
Re: Pfizer Course Has 23% Efficacy Vs. Omicron in S. African Study
by ga10 Sun Dec 12, 2021 5:15 pm
Mấy tuần trước báo nói thằng Moderna more effective hơn thằng Pfizer cho nên tui kêu OX switch sang Moderna for booster shot. Bây giờ thì nói thằng Pfizer better bởi vậy OX tui có dịp nói "I told you so!". 
ga10
Re: Pfizer Course Has 23% Efficacy Vs. Omicron in S. African Study
by 8DonCo Sun Dec 12, 2021 6:40 pm
ga10 wrote:Mấy tuần trước báo nói thằng Moderna more effective hơn thằng Pfizer cho nên tui kêu OX switch sang Moderna for booster shot. Bây giờ thì nói thằng Pfizer better bởi vậy OX tui có dịp nói "I told you so!".
Data của Moderna và Omicrom chưa có
cái bà nói là cho Delta
_________________
8DonCo
Re: Pfizer Course Has 23% Efficacy Vs. Omicron in S. African Study
by ga10 Sun Dec 12, 2021 7:24 pm
Mà sao chích booster chỉ có 23% effective thôi cũng 0 sound very promising. Nhớ 2 mũi đầu họ nói effective in the 90+% mấy con lúc đầu mà.
Tui sợ chích hoài cái body của mình trở thành ổ COVID bửa nào immune systems yếu đi nó quật mình lại internally!
Tui sợ chích hoài cái body của mình trở thành ổ COVID bửa nào immune systems yếu đi nó quật mình lại internally!
ga10
Re: Pfizer Course Has 23% Efficacy Vs. Omicron in S. African Study
by 8DonCo Sun Dec 12, 2021 7:34 pm
Hình như bà không có đọc
A two-shot course of Pfizer Inc.’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa.
A two-shot course of Pfizer Inc.’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa.
_________________
8DonCo
Sponsored content
Similar topics» Corona: Israel cảnh báo: Delta trở lại? Lo sợ Delta trở lại
» Beijing half marathon winners stripped of medals after African trio..
» A third of Covid-19 survivors suffer 'brain disease,' study shows
» Zero-calorie sweetener linked to heart attack and stroke, study finds
» Omicron
» Beijing half marathon winners stripped of medals after African trio..
» A third of Covid-19 survivors suffer 'brain disease,' study shows
» Zero-calorie sweetener linked to heart attack and stroke, study finds
» Omicron
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum